

1 Comparison of Epidermal Growth Factor Levels in the Gingival 2 Crevicular Fluid of Patients with Gingivitis and Advanced 3 Periodontitis

4 Mojtaba Bayani¹

5 ¹ Tehran University Of Medical Sciences

6 *Received: 15 April 2015 Accepted: 30 April 2015 Published: 15 May 2015*

7 **Abstract**

8 Aims: The aim of this study was to evaluate and compare epidermal growth factor (EGF)
9 levels in gingival crevicular fluid (GCF) in patients with gingivitis and advanced periodontitis.
10 Study design: Department of Periodontics, Tehran University of Medical Sciences, between
11 March 2012 and August 2013. Materials and methods: In the present cross-sectional/
12 analytical study EGF levels were evaluated in the GCF samples of patients with gingivitis and
13 advanced periodontitis. The subjects consisted of 11 and 13 patients with advanced
14 periodontitis and gingivitis, respectively. Whatman absorbent papers, placed in a depth of 1
15 mm in the pocket for 1 minute, were used to collect GCF samples, which were evaluated by
16 ELISA for EGF concentrations. Data were analyzed using SPSS 22.0. Independent t-test was
17 used for comparison of EGF levels in the GCF samples of patients. Statistical significance was
18 defined at $P < .05$. Correlation between clinical parameters and EGF concentrations was
19 analyzed using Spearman rho test. Statistical significance was set to $P < .01$.
20

21 *Index terms*— epidermal growth factor, gingivitis, periodontitis, gingival crevicular fluid.

22 **1 I. Introduction**

23 Periodontal diseases constitute one of the major health-related problems of teeth and their supporting structures,
24 with a high prevalence rate in the general population all over the world [1,2]. Evidence indicates that major risk
25 factors in periodontal diseases include poor oral hygiene, tobacco use, severe alcoholism, stress and diabetes.

26 Advanced chronic periodontitis results from the interaction between gram-negative bacteria and the host's
27 inflammatory response, finally resulting in tissue destruction and loss of teeth [3][4][5]. Presence of various
28 bacterial products in the cellular components of gingival tissues has been reported to be a factor involved in
29 the activation of cellular processes, leading to the destruction of connective tissue and bone [3,6]. Pathogenic
30 bacteria can evade recognition and elimination by the host defense system and can inactivate the cells and
31 humoral factors of the host, directly and indirectly affecting tissues [6]. The immune cells of the periodontium
32 secrete proinflammatory mediators in response to periodontal pathogens and their endotoxins [7], one of which
33 is cytokines in the gingival crevicular fluid (GCF).

34 In the same context, active cytokines which destroy tissues have been introduced as the main factors involved
35 in the destruction of connective tissue adhesion and bone loss. Different kinds of cytokines are released by
36 lymphocytes, monocytes and non-immune cells, such as fibroblasts and epithelial and endothelial cells in the
37 inflamed periodontal tissues [8]. Cytokines are soluble glycoproteins, which function as signaling molecules for
38 the control, behavior harmony and cell function.

39 On the other hand, growth factors are generally considered subsets of cytokines. These factors are biologic
40 mediators which regulate cellular migration in the connective tissue and proliferation and synthesis of proteins
41 and other extracellular matrix cells. Reaction of target cells to growth factors depends on the expression of their

6 D) REGISTRATION OF DATA

43 specific receptors. These receptors are membrane antigens which produce intercellular signals when they bind to
44 growth factors and induce chemotaxis, cellular growth, and synthesis and differentiation of extracellular matrix
45 [9]. It has been shown that receptors of growth factors are very important in inducing periodontal disease and
46 regeneration in a rat model. [10].

47 Periodontal diseases comprise a number of chronic and acute inflammatory processes in response to bacterial
48 products or components, which are diagnosed through resorption of some extracellular matrix components,
49 including bone resorption. Severe destruction of periodontal tissues is probably related to an increased activity
50 of proteinases derived from the host, including collagenase and gelatinase [11]. Since epidermal growth factor
51 (EGF) is an important activator of collagenase and gelatinase, its presence in the gingival tissues of the rats has
52 been evaluated and confirmed [12]. In addition, expression of gingival EGF has been reported during inflammatory
53 processes in rat. So, it appears EGF is an important mediator in the pathogenesis of periodontal diseases [13].

54 Successful and effective treatment of chronic periodontitis depends on early diagnosis of the disease. As a result,
55 even in the case of aggressive periodontitis, too, early diagnosis might to a great extent prevent subsequent
56 problems and disturbances resulting from the condition. It can be concluded that recognition of risk factors
57 involved in the pathogenesis of the condition is one of the most important factors contributing to the diagnosis
58 and effective treatment of any disease condition [7].

59 Saliva, serum, urine and GCF samples have been used for evaluation of periodontal diseases. Some evaluations
60 have shown that serum and urine can only be used for differential diagnostic tests because they pass through
61 different body parts and a large number of constituents are incorporated into or deleted from serum and urine
62 during these passes. Saliva, too, has some problems in the firm diagnosis because it contains many constituents
63 derived from various sources, including salivary glands, serum, GCF, bacteria and foreign bodies [14]. However
64 GCF is superior to other sources because it is easy to collect using a non-invasive procedure and it contains some
65 products derived from the host, dental plaque and the products resulting from their interaction.

66 This study was carried out to evaluate and compare EGF levels in the GCF samples of patients with gingivitis
67 and advanced periodontitis.

68 2 II. Materials and Methods

69 3 a) Population Samples

70 The present cross-sectional/analytical study was conducted according to the guidelines of the Helsinki Declaration
71 of 1975, revised in 2000. The research protocol was approved by the Ethics Committee of the Dental Research
72 Center of Tehran University of Medical Sciences. The study population consisted of patients referred to the
73 Department of Periodontics, Tehran University of Medical Sciences, between March 2012 and August 2013
74 intended for periodontal treatment teeth that met the inclusion and exclusion criteria of the study.

75 11 patients with advanced periodontitis (5 females and 6 males with an age range of 30 to 65 years) and 13
76 patients with gingivitis (7 females and 6 males with an age range of 20 to 47 years) were included in the study.
77 None-random sampling technique was applied based on the subjects available.

78 4 b) Inclusion Criteria

79 The inclusion criteria for patients with advanced periodontitis were as follows: attachment loss of \geq 5mm,
80 periodontal pocket depth > 3 mm, radiographic signs of bone loss and thorough systemic health.

81 The inclusion criteria for patients with gingivitis were as follows: presence of gingival inflammation with
82 bleeding on probing, no attachment loss, any characteristics of periodontitis, any history of previous scaling or
83 root planing, absence of bone loss on panoramic radiographs, periodontal pockets depth of \geq 3 mm and thorough
84 systemic health.

85 Based on our previous study, the amount of GCF is absolutely low and in many cases we were not able to
86 calculate it [18]. Therefore, healthy controls were not included in this study and the control was considered as
87 zero.

88 5 c) Exclusion Criteria

89 The exclusion criteria consisted of a history of systemic diseases with an effect on periodontal tissues, use of
90 antibiotics six month before the study, periodontal treatment during the previous year, pregnancy and lactation,
91 history of any prophylactic procedures, smoking, and lack of patient compliance.

92 6 d) Registration of Data

93 The patients received explanations about the study design and consent forms were obtained. The demographic
94 data of the subjects were recorded, which consisted of name, age, sex, occupation, educational status, presence
95 of systemic conditions, use of antibiotics and frequency of use, pregnancy and lactation as well as a history of
96 any periodontal treatment.

97 7 e) Ethical considerations

98 In the present study, samples were collected using sample non-invasive techniques after the subjects signed
99 informed written consent forms. In addition, all the laboratory steps of the study on patient samples, except
100 for sampling procedures, were carried out in the absence of the patients. To this end, Whatman absorbent
101 papers (P&R Labpak, united kingdom, catalog number #1001 110), which had previously been cut to 2×8 mm
102 dimensions and sterilized in a dry oven, were used (Figure 2). Each paper strip was placed in a depth of 1 mm in
103 the pocket for 1 minute (Figure 3). Subsequently, the patients' panoramic radiographs were used to evaluate and
104 record bone loss (vertical and/or horizontal) generally in each patient (Figure 1). If patients were suffering from
105 BOP without any bone loss, then they were assigned to the gingivitis group and if in addition to BOP, advanced
106 bone loss (Advanced periodontitis) were observed these subjects were assigned to the periodontitis group.

107 Then, the number of teeth in each patient's mouth was recorded. Locations selected for sampling in the
108 gingivitis and advanced periodontitis groups patients were 4 per-determined sites. (mesial, mid, distal aspect
109 in buccal and mid lingual) , which included the deepest pocket in each quadrant and the following procedure was
110 used to extract [15,16] GCF: 4 samples were collected and finally a sufficient amount of GCF was provided for
111 measurements.

112 8 g) Laboratory procedure of samples and buffer preparation 113 for ELISA test

114 The solution pH value was adjusted at 7.8 by stepwise adding of hydrochloric acid (0.5 mmol/L). Finally, the
115 volume was adjusted at 100 mL by incorporating distilled water. Solutions produced this way are stable, capable
116 of being preserved for a period of 6 months at -4°C. To achieve an identical test condition for all the samples, 300
117 ?L of the solution was placed in each Eppendorf tube. The samples were preserved at -20°C in the laboratory until
118 sufficient number of samples was collected for the use of an ELISA kit. Finally, the samples were simultaneously
119 evaluated.

120 Before evaluation of the samples with ELISA, all the samples were placed in a mixer and homogeneously
121 dissolved in the buffer solution. . In this way, each patient had only one sample for evaluation by ELISA.

122 9 h) ELISA Test

123 A standardized curve was used to determine the concentration of the samples in ng/mL. The laboratory steps of
124 ELISA test procedure was carried out carefully according to company instruction (R&D Systems, Minneapolis,
125 MN, USA Catalog number # DEG00*).

126 i) Statistical analysis SPSS 22 .0 was used for statistical analysis. To this end, central dispersion parameters
127 of age and EGF levels of GCF were determined and reported. Independent t-test was used to compare EGF
128 levels in the GCF samples of patients with gingivitis and advanced periodontitis at a significant level of P<.05.
129 To determine the correlation of clinical parameters and EGF levels of GCF, Spearman's rho (2-tailed) test was
130 used. Level of statistical significance for this test was set to <.01.

131 10 III. Results

132 Based on the results, evaluation of EGF levels in the GCF samples of the subjects showed that the mean
133 levels in patients with gingivitis and advanced periodontitis were 68.07 ng/mL (SD=6.45) and 43.61 ng/mL
134 (SD=.18), respectively (Table1). Independent t-test showed significant differences between the two groups of
135 patients in EGF levels of GCF, with significantly higher levels in patients with gingivitis compared to those with
136 advanced periodontitis (P<.001). Evaluation of EGF in the GCF of patients revealed mean concentrations of
137 68.07 ng/mL and 43.61 ng/mL in patients with gingivitis and advanced periodontitis, respectively, demonstrating
138 a significantly lower level of the factor in the GCF of patients with advanced periodontitis compared to those with
139 gingivitis. Moreover, EGF concentrations in GCF have shown to be in significant negative correlation with PPD
140 and CAL (P<.001). In other words, the concentration of EGF had significantly decreased with the progression
141 of periodontal disease.

142 According to Oxford et al (2000) cells in the injured area or with periodontal disease are able to synthesize
143 growth factors and can have an effective role in wound healing processes, evaluation of the mechanisms associated
144 with the course of periodontal diseases or other oral manifestations is of great significance [17], although some
145 studies [17,18] demonstrated that the role of EGF in saliva may be similar to its role in GCF as a prognostic
146 factor for periodontal disease, authors believe evaluating the EGF levels in GCF that carefully was isolated from
147 the saliva contamination, can show more solidarity with progression of periodontal disease.

148 Moosavijazi et al (2014) reported that significant differences between the three under study groups (patient with
149 periodontitis and patient with gingivitis and healthy controls) in the salivary level of EGF, with a significant
150 decrease in EGF levels with the progression of periodontal disease. Given a significant decrease in the salivary
151 level of EGF in patients with periodontal disease, it appears that change in EGF level is an important mechanism
152 associated with the pathogenesis of periodontal disease [18]. This conclusion is in agreement with our findings
153 in the GCF. It is suggested to design studies in the future that can evaluate and compare EGF concentrations

10 III. RESULTS

154 in saliva and GCF in different periodontal health conditions. By the suggested study design, we can find which
155 one of saliva or GCF can be more helping in the determination of periodontal deterioration.

156 It must be stated that although commonly in studies where more than one cytokine evaluated, the concentration
157 is adjusted for the whole mg of proteins, however, in the present study, only EGF was evaluated. Therefore,
158 there was no need to adjust the concentration for the whole mg of proteins. In a study by Chang et al (1996),
159 concentration of EGF in the GCF samples collected from deep pockets (>5 mm) was reported to be approximately
160 one-third of that in samples collected from shallow pockets (<5 mm) [19]. Since deep pockets have gingival indexes
161 and GCF flow rates higher than those of shallow pockets, it appears this decrease in the concentration of EGF is
162 associated with an increase in the severity of inflammation. The results of the present study confirmed the results
163 of the mentioned study because there was a decrease in the EGF levels of GCF with an increase in PPD and
164 CAL, which were higher in patients with periodontitis compared to patients with gingivitis. An increase in the
165 GCF flow, which is one of the complications of inflammation, might exert a dilutive effect on the concentration
166 of EGF. This dilutive effect might also be attributed to an increase in its stasis in the area after an increase in
167 its volume in the more superficial areas of the pockets or an increase in the permeability of vessels, leading to
168 more leakage.

169 On the other hand, not all studies reported the same findings. Mogi et al (1999) evaluated and compared the
170 concentrations of a number of cytokines including EGF in the GCF in different conditions of periodontal tissues.
171 They found no statistically significant difference between EGF concentrations in comparison of healthy controls
172 and periodontitis patients [20]. Laurina et al (2009) reported that the highest expression of growth factors and
173 their receptors are found in the gingival epithelium in patients with periodontitis and at the same time, normal
174 gingival tissues exhibit low levels of growth receptors compared to inflamed tissue [21].

175 Generally, growth factors are considered a kind of cytokines and it appears EGF has an important role
176 in the pathogenesis of periodontal disease because it induces the production of plasminogen, collagenase and
177 gelatinase activators [12,22]. Plasminogen activator can convert plasminogen into plasmin, which consists of a
178 broad range of proteins and has the potential to decrease extracellular matrix components, such as laminin and
179 fibronectin [12]. In addition, it can degrade collagen by activating latent collagenase [12]. Furthermore, EGF
180 can increase endothelial cell migration and production of plasminogen activators, which are inhibited by TNF
181 [23]. On the other hand, it has been shown that EGF can induce proliferation of epithelial cells in inflammatory
182 periapical lesions [24]. This inductive activity might be effective in the proliferation of junctional epithelium
183 during formation of periodontal pockets.

184 Since activators of collagenase, gelatinase and plasminogen and TNF, IL-1 and prostaglandin E2 all have a
185 role in tissue destruction in periodontal diseases, including bone loss, the results of the present study, in relation
186 to decreases in growth factor levels concomitant with the progression of periodontal disease, showed that EGF
187 might be an important regulator of the pathogenesis of periodontal disease due to its complex reactions with the
188 factors mentioned above.

189 The low molecular weight polypeptide, EGF, plays important roles in epithelial growth and differentiation and
190 in wound healing by binding to a cell surface receptor. In 1991, the gingival specimens of periodontally healthy
191 subjects and patients with adult (AP) and juvenile periodontitis (JP) were examined by immunohistochemistry
192 and a monoclonal antibody (mAb) directed against the EGF receptor [25]. They reported that EGF receptors
193 were highly expressed on the surface of basal cell layers of gingival epithelium. However, in normal junctional
194 epithelium, specific labeling was faint or negative. These findings showed that receptors are poorly expressed or
195 absent in these cells. Therefore, EGF is involved in control of epithelial growth and differentiation in periodontal
196 tissues. Considering that EGF receptors have been studied [25], we suggest that future studies should be designed,
197 so that the expression of gingival receptors of EGF together with other cytokines in different types of periodontal
198 diseases to be evaluated. This will help in obtaining more accurate results.

199 The action of some polypeptide growth factors in patients with rapidly progressive periodontitis (RPP) during
200 periodontal therapy was studied in 1995 using alloplastic grafts [26]. They measured the levels of epidermal
201 growth factor (EGF), fibroblastic growth factor (FGF), platelet-derived growth factor (PDGF) and transforming
202 growth factor beta (TGF beta) in both blood serum and saliva. The results showed significant differences in the
203 behaviour of growth factors in blood referred to EGF and PDGF. It was found that serum concentration of RPP
204 patients were higher at the beginning of the study and after three months as compared to control group. On the
205 other hand, the concentrations of EGF, PDGF and FGF were not significantly different in salivary samples as
206 compared with control group.

207 Cytokines derived from resident and inflammatory cells during inflammation have important roles for diagnostic
208 purposes. In 2003, the evidences of a study was released in which the area fraction (AA%) occupied by collagen
209 fibers and the amount of cytokines including interleukin (IL)-1beta, IL-4, IL-6, tumor necrosis factor (TNF)-
210 alpha, transforming growth factor (TGF)-beta, and epidermal growth factor (EGF) had been investigated [27].
211 They aimed to show correlation between such cytokines, collagen degradation, and the gingival index. The
212 study was designed on culturing gingival tissue specimens of patients with mild, moderate and severe gingival
213 inflammation to be compared to the samples obtained from healthy. The cytokines present in the culture media
214 were then quantified by enzyme-linked immunosorbent assay (ELISA). They calculated then the area fraction
215 (AA%) occupied by the gingival fibers through automated image analysis. Based on their results, significant
216 differences were observed between means of AA% in examined groups for collagen fibers as compared to controls.

217 They reported significant increases of IL-1beta (groups 3 and 4), IL-6, and TNFalpha (group 3); a significant
218 decrease of IL-4 (groups 2, 3, and 4) and TGF-beta (groups-2 and, 3); and no change of EGF. It was also reported
219 that collagen AA% was significantly correlated with the amounts of IL-4 and TGF-beta, and significantly inversely
220 correlated with the amounts of IL-1beta for all 3 inflamed groups and IL-6 and TNF-alpha for groups 2 and 3. It
221 was concluded that EGF was not changed in inflamed gingival tissue and that IL-1beta and IL-4 were particularly
222 and intensively correlated with collagen loss. These results expressed that cytokines could be markers of clinical
223 severity during active periodontitis.

224 It is suggested that detecting alternations in different compounds present in gingival crevicular fluid (GCF)
225 could be considered as potent indicators of periodontal disease activity. In a 2006 study, human cytokine array
226 V, was used in order to determine the profile of cytokines in GCF from chronic periodontitis patients and to
227 be compared with healthy subjects [28]. Their statistically analyzed results showed the presence of only 10
228 cytokines in periodontally healthy sites, while this number raised to about 4 times (36 cytokines) in the cases
229 with periodontal disorder. Among the evaluated cytokines, EGF and some others were reported to be significantly
230 higher in diseased sites than healthy sites. In contrast to the present study in which a quantitative method was
231 utilized, in the above-mentioned research a semi-quantitative one was used. So, it is not possible to compare the
232 EGF concentrations between the two studies. Moreover, in the current study, EGF was found to be at lower
233 amounts in periodontitis in comparison to gingivitis. Overall, from the results of the abovementioned and the
234 present studies, it can be hypothesized that EGF expression in GCF will increase eventually as gingivitis emerges
235 and then will decrease as periodontitis develops, but to a level still significantly higher than health condition.
236 But this hypothesis has to be confirmed by further studies.

237 The effect of epidermal growth factor (EGF) on the expression of MMPs and TIMPs in cultured human gingival
238 fibroblasts has also been reported [29]. It was found that MMP-1, 3, 7 and 11 expressions were increased at all
239 EGF concentrations. However, at the lowest EGF concentration, MMP-1, 3 and 7 showed only small expression
240 while MMP-11 presented the greatest expression. On the other hand, at higher EGF concentrations, MMP-1,
241 3 and 7 presented greater upregulation, and MMP-11 lower up-regulation. The study suggested that EGF may
242 play a role in periodontal destruction and wound repair.

243 *Porphyromonas gingivalis* is one of the most important periodontal pathogens. It has been shown that this
244 bacteria have the ability to inactivate EGF by its peptidylarginine deiminase enzyme [30]. This finding may
245 suggest a potential mechanism for the progression of periodontal disease. Because, based on the discussed articles,
246 EGF has a protective role in the periodontium. Based on results of our present study, there is a significant decrease
247 in EGF levels in the GCF with progression of periodontal disease from gingivitis to periodontitis. So, it may
248 propose another potential mechanism for periodontal destruction; reduction in the quantity of EGF in the GCF.
249 But this suggestion has to be confirmed by performing studies regarding the possible reasons for this reduction.

250 11 V. Conclusions

251 There is a significant decrease in EGF levels with exacerbation of periodontal disease. On the whole, given the
252 significant decrease in EGF levels in the GCF samples of patients with periodontal disease, it is suggested that
253 alterations in the concentrations of EGF in the GCF may predict the pathogenesis of periodontal diseases. Future
254 studies regarding the effect of periodontal treatment on EGF concentrations in GCF samples of patients with
255 periodontal disease is suggested.

256 12 Volume XV Issue III Version I

257 Year 2015 () J 1




Figure 1: Figure 1 :



Figure 2: Figure 2 :




Figure 3: Figure 3 :



Figure 4: Figure 4 :




Figure 5: Figure 5 :



6

Figure 6: Figure 6 :



7

Figure 7: Figure 7 :

1

Group	No	Mean	SD	Std error	95% confidence interval	Upper bound	Lower bound
Gingivitis	13	68.07	6.45	1.79	71.97	64.17	
Periodontitis	11	43.61	6.18	1.86	47.77	39.46	

Figure 8: Table 1 :

3

PI	BOP	PPD	CAL	Age
----	-----	-----	-----	-----

[Note: **Significant correlation]

Figure 9: Table 3 :

2

Figure 10: Table 2 :

258 .1 VI. Acknowledgement

259 The authors would like to thank Dr. MJ Kharrazifard for his valueable help regarding the data analysis of this
260 study.

261 .2 Consent

262 All authors declare that written informed consent was obtained from the patient (or other approved parties) for
263 publication of this study and accompanying images. A copy of the written consent is available for review by the
264 Editorial office/Chief Editor/Editorial Board members of this journal.

265 .3 Ethical Approval

266 All authors hereby declare that all experiments have been examined and approved by the appropriate ethics
267 committee and have therefore been performed in accordance with the ethical standards laid down in the 1964
268 Declaration of Helsinki.

269 [Philadelphia ()] , Usa Philadelphia . 2012. 6 p. .

270 [Page et al. (2000 1997)] 'Advance's pathogenesis of periodontitis: summary of developments, clinical implications
271 and future directions'. R C Page , S Offenbacher , H E Schroeder , G J Seymour , K S Kornman .
272 *Periodontol* 2000 1997. 14 p. .

273 [Ejeil et al. (2003)] 'Are cytokines linked to collagen breakdown during periodontal disease progression?'. A L
274 Ejeil , F Gaultier , S Igondjo-Tchen , K Senni , B Pellat , G Godeau , B Gogly . *J Periodontol* 2003 Feb. 74
275 (2) p. .

276 [Newman et al.] *Clinical Periodontology*, M G Newman , H H Takei , A F Carranza . WB Saunders Co. (9th ed)

277 [Moosavijazi et al. ()] 'Comparison of Salivary Epidermal Growth Factor Levels in Patients with Gingivitis and
278 Advanced Periodontitis and Healthy Subjects'. M Moosavijazi , Rasouli Ghahroudi , A Yaghoobee , S Bayani
279 , M Salehi , E Sadrimanesh , R . *Journal of Dentistry* 2014. Tehran.

280 [Kamma et al. (2004)] 'Cytokine profile in gingival crevicular fluid of aggressive periodontitis: influence of
281 smoking and stress'. J J Kamma , C Giannopoulou , V G Vasdekis , A Mombelli . *J Clin Periodontol*
282 2004 Oct. 31 (10) p. .

283 [Fujihashi et al. ()] 'Cytokines and periodontal disease: immunopathological role of interleukins for B cell
284 responses in chronic inflamed gingival tissues'. K Fujihashi , Y Kono , K W Beagley , M Yamamoto , J
285 R Mcghee , J Mestecky , H Kiyono . *J Periodontol* 1993. 64 p. .

286 [Giannopoulou et al. (2003)] 'Effect of inflammation, smoking and stress on gingival crevicular fluid cytokine
287 level'. C Giannopoulou , J J Kamma , A Mombelli . *J Clin Periodontol* 2003 Feb. 30 (2) p. .

288 [Oxford et al. ()] 'Elevated levels of human salivary epidermal growth factor after oral and juxtaoral surgery'. G
289 E Oxford , R Jonsson , J Oloffson , T Zelles , M G Humphreys-Beber . *J Oral Maxillofac Surg* 1999. 57 p. .

290 [Papapanou ()] 'Epidemiology of periodontal disease: An update'. P N Papapanou . *J Int Acad Periodontol* 1999.
291 1 p. .

292 [Tajima et al. ()] 'Epidemral growth factor expression in junctional epithelium of rat gingival'. Y Tajima , S
293 Yokose , M Kahsimata , M Hiramatsu , N Minami , N Utsumi . *J Periodont Res* 1992. 27 p. .

294 [Chang et al. ()] 'Epidermal growth factor in gingival crevical fluid and its binding capacity in inflamed and
295 non-inflamed human gingiva'. K-M Chang , N Lehrhaupt , L M Lin , J Feng , C-Y Wu-Wang , S-L Wang .
296 *Archs Oral Biol* 1996. 41 (7) p. .

297 [Parkar et al. ()] 'Expression of growth-factor receptors in normal and regenerating human periodontal cells'. M
298 H Parkar , L Kuru , M Giouzeli , I Olsen . *Arch Oral Biology* 2002. 46 p. .

299 [Laurina et al. ()] 'Growth factors/ cytokines/defensins and apoptosis in periodontal pathologies'. Z Laurina , M
300 Pilmane , R Care . *Stomatologija* 2009. 11 (2) p. .

301 [Nordlund et al. ()] 'Immunohistochemical localization of epidermal growth factor receptors in human gingival
302 epithelia'. L Nordlund , M Hormia , L Saxen , I Thesleff . *J Periodontal Res* 1991. 26 (4) p. .

303 [Seymour ()] 'Importance of the host response in the periodontium'. G J Seymour . *J Clin Periodontol* 1991. 18
304 p. .

305 [Pyrc et al. ()] 'Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism
306 for periodontal tissue damage'. K Pyrc , A Milewska , T Kanytka , A Sroka , K Maresz , J Koziel . *Infect
307 Immun* 2013. 81 (1) p. .

308 [Mogi et al. ()] 'Interleukin 1?, interleukin-6, ? 2 -microglobulin, and transforming growth factor-alpha in
309 gingival crevicular fluid from human periodontal disease'. M Mogi , J Otogoto , N Ota , H Inagaki , M
310 Minami , K Kojima . *Archives Oral Biol* 1999. 44 p. .

311 [Lyons et al. ()] 'Interleukin-1?3 and transforming growth factor-?/epidermal growth factor induce expression
312 of Mr 95,000 type IV collagenase/gelatinase and interstitial fibroblasttype collagenase by rat mucosal
313 keratinocytes'. J G Lyons , B Birkedal-Hansen , M C Pierson , J M Whitelock , H Birkedal-Hansen . *J
314 Biol Chem* 1993. 268 p. .

315 [Reynolds and Meikle ()] 'Mechanisms of connective tissue matrix destruction in periodontitis'. J J Reynolds ,
316 M C Meikle . *Periodontol* 2000. 1997. 14 p. .

317 [Murphy et al. ()] 'Physiological mechanisms for metalloproteinase activation'. G Murphy , R Ward , J Gavrilovic
318 , S Atkinson . *Matrix* 1991. 1 p. . (Suppl)

319 [Pietruska et al. ()] 'Polypeptide growth factors in the course of surgical periodontal treatment'. Md1 Pietruska
320 , J K Pietruski , W Stokowska . *Rocz Akad Med Bialymst* 2000. 45 p. .

321 [Sakai et al. (2006)] 'Profiling the cytokines in gingival crevicular fluid using a cytokine antibody array. Sakai'.
322 A1 Sakai , M Ohshima , N Sugano , K Otsuka , K Ito . *J Periodontol* 2006 May. 77 (5) p. .

323 [Ekuni et al. ()] 'Regulation of epithelial cell growth factor receptor protein and gene expression using a rat
324 periodontitis model'. D Ekuni , J D Firth , E E Putnins . *J Periodontal Res* 2006. 41 p. .

325 [Thomas et al. ()] 'Risk factor for periodontitis'. E Thomas , V Dyke , D Sheilesh . *J Int Acad Periodontol* 2005.
326 7 p. .

327 [Birkedal-Hansen ()] 'Role of matrix metalloproteinases in human periodontal diseases'. H Birkedal-Hansen . *J
328 Periodontol* 1993. 64 p. .

329 [Oxford et al. ()] 'Salivary EGF levels reduced in diabetic patients'. G E Oxford , L Tayari , M D Barfoot , A B
330 Peck , Y Tanaka , M G Humphreys-Beher . *J Diabetes and Its Complications* 2000. 14 p. .

331 [The American Academy of Periodontology. The pathogenesis of periodontal diseases (information paper) J Periodontol ()]
332 'The American Academy of Periodontology. The pathogenesis of periodontal diseases (information paper)'.
333 *J Periodontol* 1999. 70 p. .

334 [Cury et al. (2007)] 'The effect of epidermal growth factor on matrix metalloproteinases and tissue inhibitors of
335 metalloproteinase gene expression in cultured human gingival fibroblasts'. P R Cury , V C De Araújo , F
336 Canavez , C Furuse , K R Leite , N S De Araújo . *Arch Oral Biol* 2007 Jun. 52 (6) p. .

337 [Petersen ()] 'The World Oral Health Report 2003: Continuous improvement of oral health in the 21st century
338 -The approach of the WHO Global Oral Health Programme'. P E Petersen . *Community Dent Oral Epidemiol*
339 2003. 31 p. .

340 [Mawatari et al. ()] 'Tumor necrosis factor and epidermal growth factor modulate migration of human microvas-
341 cular endothelial cells and production of tissue-type plasminogen activator and its inhibitors'. M Mawatari ,
342 K Okamura , T Matsuda , R Hamanaka , H Mizoguchi , K Higashio , K Kohno , M Kuwano . *Expl Cell Res*
343 1991. 192 p. .